Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Differences in effect of mepolizumab and benralizumab on resident and inflammatory eosinophils
2019-004676-18Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial in eosinophilic asthma (EA) and asthma comparing Nucala arm with Fasenra arm (2 arms). Primary endpoint: Number of eosinophils in rectal tissue. Started Nov 2020; status: completed.
02
Drugs
mepolizumabbenralizumab
03
Conditions
eosinophilic asthma (EA)asthma
Beyond the preview
Go deeper on 2019-004676-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004676-18.